JP2003512434A5 - - Google Patents

Download PDF

Info

Publication number
JP2003512434A5
JP2003512434A5 JP2001532793A JP2001532793A JP2003512434A5 JP 2003512434 A5 JP2003512434 A5 JP 2003512434A5 JP 2001532793 A JP2001532793 A JP 2001532793A JP 2001532793 A JP2001532793 A JP 2001532793A JP 2003512434 A5 JP2003512434 A5 JP 2003512434A5
Authority
JP
Japan
Prior art keywords
renal failure
chronic renal
patient
dialysis
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001532793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512434A (ja
Filing date
Publication date
Priority claimed from DE19951471A external-priority patent/DE19951471A1/de
Application filed filed Critical
Publication of JP2003512434A publication Critical patent/JP2003512434A/ja
Publication of JP2003512434A5 publication Critical patent/JP2003512434A5/ja
Pending legal-status Critical Current

Links

JP2001532793A 1999-10-26 2000-10-24 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用 Pending JP2003512434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951471A DE19951471A1 (de) 1999-10-26 1999-10-26 Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
DE19951471.2 1999-10-26
PCT/EP2000/010462 WO2001030376A2 (de) 1999-10-26 2000-10-24 Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen

Publications (2)

Publication Number Publication Date
JP2003512434A JP2003512434A (ja) 2003-04-02
JP2003512434A5 true JP2003512434A5 (enExample) 2008-11-13

Family

ID=7926884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001532793A Pending JP2003512434A (ja) 1999-10-26 2000-10-24 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用

Country Status (7)

Country Link
US (1) US6831064B1 (enExample)
EP (1) EP1223968B1 (enExample)
JP (1) JP2003512434A (enExample)
AT (1) ATE239497T1 (enExample)
DE (2) DE19951471A1 (enExample)
ES (1) ES2198359T3 (enExample)
WO (1) WO2001030376A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
ES2575397T3 (es) * 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
EP2078530A1 (en) 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2948165A2 (en) 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
WO2022029499A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
WO2022029497A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2819467B2 (ja) * 1987-03-02 1998-10-30 ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー 新規なカルジオジラチン断片およびその製造方法
US5691310A (en) 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
DE4216133A1 (de) * 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
PL191377B1 (pl) * 1996-12-31 2006-05-31 Ajay Gupta Kompozycje farmaceutyczne do hemodializy i dializy otrzewnowej oraz sposób hemodializy i dializy otrzewnowej

Similar Documents

Publication Publication Date Title
ATE334710T1 (de) Kostengüstige infusionsvorrichtung
AU7368896A (en) Limited backflow reflux valve
CA2312468A1 (en) Catheter system of specified dead space for the delivery of a low volume liquid bolus
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
FR2806918B1 (fr) Catheter pour l'administration specifique d'un medicament
WO2001019334A3 (en) Pharmaceutical solutions of levosimendan
CA2544963A1 (en) Myo-inositol hexaphosphate for topical use technical field
WO2000064456A3 (en) Substitution infusion fluid and citrate anticoagulation
JP2003512434A5 (enExample)
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
Schwenk et al. The pharmacokinetics of acetazolamide during CAPD
ES2164630T3 (es) Sistema combinado de varios aparatos medicos para anestesia total intravenosa.
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
CA2238920A1 (en) Nephroprotective pharmaceutical composition and use thereof
Gray et al. Chlormethiazole sedation for critically ill patients in renal failure
KR20240008579A (ko) 정맥주사 연결용 2방향 커넥터
李麗琴 et al. The Use of Diazepam, Midazolam and Propofol for Sedation in the Surgical Intensive-Care Unit
Agraharkar Multiple drugs Hypokalaemia and lack of efficacy
KR900013956A (ko) 디메르캅토숙신산(dmsa)으로 규소를 감소시키는 방법
Zhonghua et al. The factors related to fungal peritonitis in patients on peritoneal dialysis
RU97121508A (ru) Способ оказания неотложной медицинской помощи при длительной компрессионной травме конечности
Janicke Factors affecting the pharmacokinetics of beta-lactam antibiotics.
MXPA03002114A (es) Uso de arginina en la preparacion de un medicamento para la prevencion y tratamiento de los efectos secundarios asociados con la administracion intravenosa de productos farmaceuticos.
Lee By the way, doctor. After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. I had been taking the 10-mg pill in the morning, but my doctor advised me to take the new, higher dose in the evening. He said most strokes and heart attacks happen in the morning, and that I could get better protection by taking the drug right before. But I read in the Health Letter a couple of months ago that you recommend morning intake, so I am confused